Synapse - Susan Prockop

Search Within

Susan E Prockop

Results (262)

Lentiviral globin gene therapy with reduced-intensity conditioning in adults with β-thalassemia: A phase 1 trial

Journal Article

Boulad, F.; Maggio, A.; Wang, X.; Moi, P.; Acuto, S.; Kogel, F.; Takpradit, C.; Prockop, S.; Mansilla-Soto, J.; Cabriolu, A.; more...
Nature Medicine (2022)

Fulltext@MSK | Save

Curative therapy for hemoglobinopathies: An International Society for Cell & Gene Therapy Stem Cell Engineering Committee review comparing outcomes, accessibility and cost of ex vivo stem cell gene therapy versus allogeneic hematopoietic stem cell transplantation

Review

Leonard, A.; Bertaina, A.; Bonfim, C.; Cohen, S.; Prockop, S.; Purtill, D.; Russell, A.; Boelens, J. J.; Wynn, R.; Ruggeri, A.; more...
Cytotherapy (2022)

Fulltext@MSK | Save

Antithymocyte globulin exposure in CD34(+) T-cell–depleted allogeneic hematopoietic cell transplantation

Journal Article

Lakkaraja, M.; Scordo, M.; Mauguen, A.; Cho, C.; Devlin, S.; Ruiz, J. D.; Klein, E.; Avecilla, S. T.; Boulad, F.; Cancio, M. I.; more...
Blood Advances (2022)

Fulltext@MSK | Save

Viral cytotoxic T lymphocytes (CTLs): From bench to bedside

Journal Article

Prockop, S. E.; Shahid, S.
Cancer Drug Discovery and Development (2022)

Fulltext@MSK | Save

Epstein-Barr virus-associated post-transplant lymphoproliferative disorders: Beyond chemotherapy treatment

Review

Shahid, S.; Prockop, S. E.
Cancer Drug Resistance (2021)

Fulltext@MSK | Save

Multicenter, open-label, phase 3 study of tabelecleucel for solid organ or allogeneic hematopoietic cell transplant recipients with Epstein-Barr virus-driven post transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE)

Meeting Abstract

Prockop, S.; Mahadeo, K. M.; Beitinjaneh, A.; Choquet, S.; Stiff, P.; Reshef, R.; Satyanarayana, G.; Dahiya, S.; Parmar, H.; Ye, W.; more...
Blood (2021)

Fulltext@MSK | Save

Overall survival by best overall response with tabelecleucel in patients with Epstein-Barr virus-driven post-transplant lymphoproliferative disease following solid organ or allogeneic hematopoietic cell transplant

Meeting Abstract

Prockop, S.; Gamelin, L.; Dinavahi, R.; Sun, Y.; Zhao, W. Z.; Galderisi, F.; Mehta, A.
Blood (2021)

Fulltext@MSK | Save

Interim results of a pilot, prospective, randomized, double-blinded, vehicle- and comparator-controlled trial on safety and efficacy of a topical inhibitor of janus kinase 1/2 (ruxolitinib INCB018424 phosphate 1.5% cream) for non- sclerotic and superficially sclerotic chronic cutaneous graft-versus-host disease

Meeting Abstract

Markova, A.; Pan, A.; Dusza, S.; Chowdhury, A.; Kukoyi, O.; Perales, M. A.; Lacouture, M.; Prockop, S.; Ponce, D. M.
Blood (2021)

Fulltext@MSK | Save

JSP191 As a single-agent conditioning regimen results in successful engraftment, donor myeloid chimerism, and production of donor derived naive lymphocytes in patients with severe combined immunodeficiency (SCID)

Meeting Abstract

Agarwa, R.; Dvorak, C. C.; Prockop, S.; Kwon, H. S.; Long-Boyle, J. R.; Le, A.; Brown, J. W.; Merkel, E.; Truong, K.; Velasco, B.; more...
Blood (2021)

Fulltext@MSK | Save

Overall survival by best overall response with tabelecleucel in patients with Epstein-Barr virus-driven post-transplant lymphoproliferative disease after solid organ transplant

Meeting Abstract

Prockop, S.; Gamelin, L.; Dinavahi, R.; Sun, Y.; Guzman-Becerra, N.; Parmar, H.
American Journal of Transplantation (2021)

Fulltext@MSK | Save